In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors
You may also be interested in...
Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
Sanofi-Aventis finally struck a deal to acquire Genzyme for $20.1 billion plus potential future payments, but successfully integrating the company remains the challenge.
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
Sanofi-Aventis Closes In On Diabetics In India; Big Push On Rural Markets And New Launches
MUMBAI - With the number of diabetics in India swelling to over 50 million this year according to multiple estimates, large brand companies are developing novel strategies and expanded services to bond with diabetes patients